Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Myeloproliferative Neoplasms
•
Hematology
What aspirin dose do you favor for thrombotic prophylaxis in myeloproliferative neoplasms?
81 mg vs 162 mg
Answer from: at Academic Institution
I generally use 81 mg twice a day. If they have had a thrombotic event, or have microvascular symptoms, then I use 81 mg BiD.
Sign in or Register to read more
14664
Related Questions
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
How does triple-negative status influence your management of ET?
What experience have you had with familial clustering of polycythemia vera?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you approach management for CCUS with severe cytopenias?
What is the risk of radiation therapy to an abdominal aortic aneurysm infiltrated by lymphoma?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?